Abstract
Rationale
Some evidence suggests a hyperdopaminergic state in posttraumatic stress disorder (PTSD). The 9-repetition allele (9R) located in the 3′ untranslated region of the dopamine transporter (DAT) gene (SLC6A3) is more frequent among PTSD patients. In vivo molecular imaging studies have shown that healthy 9R carriers have increased striatal DAT binding. However, no prior study evaluated in vivo striatal DAT density in PTSD.
Objectives
The objective of this study was to evaluate in vivo striatal DAT density in PTSD.
Methods
Twenty-one PTSD subjects and 21 control subjects, who were traumatized but asymptomatic, closely matched comparison subjects evaluated with the Clinician-Administered PTSD Scale underwent a single-photon emission computed tomography scan with [99mTC]-TRODAT-1. DAT binding potential (DAT-BP) was calculated using the striatum as the region of the interest and the occipital cortex as a reference region.
Results
PTSD patients had greater bilateral striatal DAT-BP (mean ± SD; left, 1.80 ± 0.42; right, 1.78 ± 0.40) than traumatized control subjects (left, 1.62 ± 0.32; right, 1.61 ± 0.31; p = 0.039 for the left striatum and p = 0.032 for the right striatum).
Conclusions
These results provide the first in vivo evidence for increased DAT density in PTSD. Increases in DAT density may reflect higher dopamine turnover in PTSD, which could contribute to the perpetuation and potentiation of exaggerated fear responses to a given event associated with the traumatic experience. Situations that resemble the traumatic event turn to be interpreted as highly salient (driving attention, arousal, and motivation) in detriment of other daily situations.
Similar content being viewed by others
References
Acton PD, Meyer PT, Mozley PD, Plössl K, Kung HF (2000) Simplified quantification of dopamine transporters in humans using [99mTc]TRODAT-1 and single-photon emission tomography. Eur J Nucl Med 27:1714–1718
Alexander GE, Crutcher MD, DeLong MR (1990) Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. Prog Brain Res 85:119–146
American Psychiatric Association (2004) Diagnostic and Statistical Manual of Mental Disorders–DSM-IV, 4th edn. American Psychiatric Association, Washington D.C
Andreoli SB, Ribeiro WS, Quintana MI, Guindalini C, Breen G, Blay SL, Coutinho ES, Harpham T, Jorge MR, Lara DR, Moriyama TS, Quarantini LC, Gadelha A, Vilete LM, Yeh MS, Prince M, Figueira I, Bressan RA, Mello MF, Dewey ME, Ferri CP, Mari JeJ (2009) Violence and post-traumatic stress disorder in Sao Paulo and Rio de Janeiro, Brazil: the protocol for an epidemiological and genetic survey. BMC Psychiatry 9:34
Argyelán M, Szabó Z, Kanyó B, Tanács A, Kovács Z, Janka Z, Pávics L (2005) Dopamine transporter availability in medication free and in bupropion treated depression: a 99mTc-TRODAT-1 SPECT study. J Affect Disord 89:115–123
Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561–571
Beck AT, Epstein N, Brown G, Steer RA (1988) An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 56:893–897
Berridge KC, Robinson TE (1998) What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev 28:309–369
Borowski TB, Kokkinidis L (1998) The effects of cocaine, amphetamine, and the dopamine D1 receptor agonist SKF 38393 on fear extinction as measured with potentiated startle: implications for psychomotor stimulant psychosis. Behav Neurosci 112:952–965
Breslau N, Davis GC, Peterson EL, Schultz L (1997) Psychiatric sequelae of posttraumatic stress disorder in women. Arch Gen Psychiatry 54:81–87
Bressan RA, Shih MC, Hoexter MQ, Lacerda AL (2007) Can molecular imaging techniques identify biomarkers for neuropsychiatric disorders? Rev Bras Psiquiatr 29:102–104
Bressan RA, Quarantini LC, Andreoli SB, Araújo C, Breen G, Guindalini C, Hoexter M, Jackowski AP, Jorge MR, Lacerda AL, Lara DR, Malta S, Moriyama TS, Quintana MI, Ribeiro WS, Ruiz J, Schoedl AF, Shih MC, Figueira I, Koenen KC, Mello MF, Mari JJ (2009) The posttraumatic stress disorder project in Brazil: neuropsychological, structural and molecular neuroimaging studies in victims of urban violence. BMC Psychiatry 9:30
Brunswick DJ, Amsterdam JD, Mozley PD, Newberg A (2003) Greater availability of brain dopamine transporters in major depression shown by [99 m Tc]TRODAT-1 SPECT imaging. Am J Psychiatry 160:1836–1841
Charney DS, Deutch AY, Krystal JH, Southwick SM, Davis M (1993) Psychobiologic mechanisms of posttraumatic stress disorder. Arch Gen Psychiatry 50:295–305
Comings DE, Muhlmann D, Gysin R (1996) Dopamine D2 receptor (DRD2) gene and susceptibility to posttraumatic stress disorder: a study and replication. Biol Psychiatry 40:368–372
Crits-Christoph P, Newberg A, Wintering N, Ploessl K, Gibbons MB, Ring-Kurtz S, Gallop R, Present J (2008) Dopamine transporter levels in cocaine dependent subjects. Drug Alcohol Depend 98:70–76
De Bellis MD, Baum AS, Birmaher B, Keshavan MS, Eccard CH, Boring AM, Jenkins FJ, Ryan ND (1999) A.E. Bennett Research Award. Developmental traumatology. Part I: biological stress systems. Biol Psychiatry 45:1259–1270
Dragan WL, Oniszczenko W (2009) The association between dopamine D4 receptor exon III polymorphism and intensity of PTSD symptoms among flood survivors. Anxiety Stress Coping 22:483–495
Drury SS, Theall KP, Keats BJ, Scheeringa M (2009) The role of the dopamine transporter (DAT) in the development of PTSD in preschool children. J Trauma Stress 22:534–539
Elman I, Lowen S, Frederick BB, Chi W, Becerra L, Pitman RK (2009) Functional neuroimaging of reward circuitry responsivity to monetary gains and losses in posttraumatic stress disorder. Biol Psychiatry 66:1083–1090
Felicio AC, Moriyama TS, Godeiro-Junior C, Shih MC, Hoexter MQ, Borges V, Silva SM, Amaro-Junior E, Andrade LA, Ferraz HB, Bressan RA (2010) Higher dopamine transporter density in Parkinson's disease patients with depression. Psychopharmacology (Berl) 211:27–31
Finlay JM, Zigmond MJ (1997) The effects of stress on central dopaminergic neurons: possible clinical implications. Neurochem Res 22:1387–1394
First M, Spitzer R, Gibbon M, Williams J (1997) Structured clinical interview for DSM-IV axis I disorders: clinical version (SCID CV). American Psychiatric Press, Washington DC
Francati V, Vermetten E, Bremner JD (2007) Functional neuroimaging studies in posttraumatic stress disorder: review of current methods and findings. Depress Anxiety 24:202–218
Fullerton CS, Ursano RJ, Epstein RS, Crowley B, Vance KL, Kao TC, Baum A (2000) Peritraumatic dissociation following motor vehicle accidents: relationship to prior trauma and prior major depression. J Nerv Ment Dis 188:267–272
Ginzburg K, Ein-Dor T, Solomon Z (2010) Comorbidity of posttraumatic stress disorder, anxiety and depression: a 20-year longitudinal study of war veterans. J Affect Disord 123:249–257
Glover DA, Powers MB, Bergman L, Smits JA, Telch MJ, Stuber M (2003) Urinary dopamine and turn bias in traumatized women with and without PTSD symptoms. Behav Brain Res 144:137–141
Hageman I, Andersen HS, Jorgensen MB (2001) Post-traumatic stress disorder: a review of psychobiology and pharmacotherapy. Acta Psychiatr Scand 104:411–422
Hamner MB, Diamond BI (1993) Elevated plasma dopamine in posttraumatic stress disorder: a preliminary report. Biol Psychiatry 33:304–306
Heim C, Nemeroff CB (2009) Neurobiology of posttraumatic stress disorder. CNS Spectr 14:13–24
Hopper JW, Pitman RK, Su Z, Heyman GM, Lasko NB, Macklin ML, Orr SP, Lukas SE, Elman I (2008) Probing reward function in posttraumatic stress disorder: expectancy and satisfaction with monetary gains and losses. J Psychiatr Res 42:802–807
Inoue T, Tsuchiya K, Koyama T (1996) Effects of typical and atypical antipsychotic drugs on freezing behavior induced by conditioned fear. Pharmacol Biochem Behav 55:195–201
Jacobsen LK, Staley JK, Zoghbi SS, Seibyl JP, Kosten TR, Innis RB, Gelernter J (2000) Prediction of dopamine transporter binding availability by genotype: a preliminary report. Am J Psychiatry 157:1700–1703
Jacobsen LK, Southwick SM, Kosten TR (2001) Substance use disorders in patients with posttraumatic stress disorder: a review of the literature. Am J Psychiatry 158:1184–1190
Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB (1995) Posttraumatic stress disorder in the national comorbidity survey. Arch Gen Psychiatry 52:1048–1060
Kung HF, Kim HJ, Kung MP, Meegalla SK, Plössl K, Lee HK (1996) Imaging of dopamine transporters in humans with technetium-99 m TRODAT-1. Eur J Nucl Med 23:1527–1530
Laasonen-Balk T, Kuikka J, Viinamäki H, Husso-Saastamoinen M, Lehtonen J, Tiihonen J (1999) Striatal dopamine transporter density in major depression. Psychopharmacology (Berl) 144:282–285
Lehto SM, Tolmunen T, Kuikka J, Valkonen-Korhonen M, Joensuu M, Saarinen PI, Vanninen R, Ahola P, Tiihonen J, Lehtonen J (2008) Midbrain serotonin and striatum dopamine transporter binding in double depression: a one-year follow-up study. Neurosci Lett 441:291–295
Lemieux AM, Coe CL (1995) Abuse-related posttraumatic stress disorder: evidence for chronic neuroendocrine activation in women. Psychosom Med 57:105–115
Leviel V (2011) Dopamine release mediated by the dopamine transporter, facts and consequences. J Neurochem 118:475–489
Malison RT, Best SE, van Dyck CH, McCance EF, Wallace EA, Laruelle M, Baldwin RM, Seibyl JP, Price LH, Kosten TR, Innis RB (1998) Elevated striatal dopamine transporters during acute cocaine abstinence as measured by [123I] beta-CIT SPECT. Am J Psychiatry 155:832–834
Meyer JH, Krüger S, Wilson AA, Christensen BK, Goulding VS, Schaffer A, Minifie C, Houle S, Hussey D, Kennedy SH (2001) Lower dopamine transporter binding potential in striatum during depression. Neuroreport 12:4121–4125
Morrow BA, Elsworth JD, Roth RH (1996) Tyrosine enhances behavioral and mesocorticolimbic dopaminergic responses to aversive conditioning. Synapse 22:100–105
Mozley PD, Stubbs JB, Plössl K, Dresel SH, Barraclough ED, Alavi A, Araujo LI, Kung HF (1998) Biodistribution and dosimetry of TRODAT-1: a technetium-99 m tropane for imaging dopamine transporters. J Nucl Med 39:2069–2076
Neria Y, Besser A, Kiper D, Westphal M (2010) A longitudinal study of posttraumatic stress disorder, depression, and generalized anxiety disorder in Israeli civilians exposed to war trauma. J Trauma Stress 23:322–330
Pezze MA, Feldon J (2004) Mesolimbic dopaminergic pathways in fear conditioning. Prog Neurobiol 74:301–320
Pruessner JC, Champagne F, Meaney MJ, Dagher A (2004) Dopamine release in response to a psychological stress in humans and its relationship to early life maternal care: a positron emission tomography study using [11 C]raclopride. J Neurosci 24:2825–2831
Pupo MC, Jorge MR, Schoedl AF, Bressan RA, Andreoli SB, Mello MF, de Jesus Mari J (2011) The accuracy of the Clinician-Administered PTSD Scale (CAPS) to identify PTSD cases in victims of urban violence. Psychiatry Res 185:157–160
Sarchiapone M, Carli V, Camardese G, Cuomo C, Di Giuda D, Calcagni ML, Focacci C, De Risio S (2006) Dopamine transporter binding in depressed patients with anhedonia. Psychiatry Res 147:243–248
Segman RH, Cooper-Kazaz R, Macciardi F, Goltser T, Halfon Y, Dobroborski T, Shalev AY (2002) Association between the dopamine transporter gene and posttraumatic stress disorder. Mol Psychiatry 7:903–907
Sher L, Oquendo MA, Li S, Burke AK, Grunebaum MF, Zalsman G, Huang YY, Mann JJ (2005) Higher cerebrospinal fluid homovanillic acid levels in depressed patients with comorbid posttraumatic stress disorder. Eur Neuropsychopharmacol 15:203–209
Shih MC, Franco de Andrade LA, Amaro E, Felicio AC, Ferraz HB, Wagner J, Hoexter MQ, Lin LF, Fu YK, Mari JJ, Tufik S, Bressan RA (2007) Higher nigrostriatal dopamine neuron loss in early than late onset Parkinson's disease?—a [99mTc]-TRODAT-1 SPECT study. Mov Disord 22:863–866
Spivak B, Vered Y, Graff E, Blum I, Mester R, Weizman A (1999) Low platelet-poor plasma concentrations of serotonin in patients with combat-related posttraumatic stress disorder. Biol Psychiatry 45:840–845
Valente NL, Vallada H, Cordeiro Q, Miguita K, Bressan RA, Andreoli SB, Mari JJ, Mello MF (2011) Candidate-gene approach in posttraumatic stress disorder after urban violence: association analysis of the genes encoding serotonin transporter, dopamine transporter, and BDNF. J Mol Neurosci 44:59–67
van de Giessen E, de Win MM, Tanck MW, van den Brink W, Baas F, Booij J (2009) Striatal dopamine transporter availability associated with polymorphisms in the dopamine transporter gene SLC6A3. J Nucl Med 50:45–52
van Dyck CH, Malison RT, Jacobsen LK, Seibyl JP, Staley JK, Laruelle M, Baldwin RM, Innis RB, Gelernter J (2005) Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. J Nucl Med 46:745–751
Weathers FW, Keane TM, Davidson JR (2001) Clinician-administered PTSD scale: a review of the first 10 years of research. Depress Anxiety 13:132–156
Weiner I (2003) The “two-headed” latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment. Psychopharmacology 169:257–297
Yang YK, Yeh TL, Yao WJ, Lee IH, Chen PS, Chiu NT, Lu RB (2008) Greater availability of dopamine transporters in patients with major depression—a dual-isotope SPECT study. Psychiatry Res 162:230–235
Yehuda R, Southwick S, Giller EL, Ma X, Mason JW (1992) Urinary catecholamine excretion and severity of PTSD symptoms in Vietnam combat veterans. J Nerv Ment Dis 180:321–325
Young RM, Lawford BR, Noble EP, Kann B, Wilkie A, Ritchie T, Arnold L, Shadforth S (2002) Harmful drinking in military veterans with post-traumatic stress disorder: association with the D2 dopamine receptorA1 allele. Alcohol Alcohol 37:451–456
Acknowledgments
This study received financial support in the form of grants provided by the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP, Foundation for the Support of Research in the State of São Paulo) to Dr. Mari (grant: 2004/15039-0) and from Instituto do Cérebro, Instituto de Ensino e Pesquisa do Hospital Israelita Albert Einstein to Dr. Bressan (grant: 148-06). This work was presented at the 65th Annual Meeting of the Society of Biological Psychiatry, May 20–22 in New Orleans, LA, USA.
Conflicts of interest
Drs. Hoexter, Fadel, Felício, Calzavara, Batista, Reis, Shih, Pitman, Andreoli, Mello, and Mari have declared no conflict of interest. Dr. Bressan has received honoraria and/or consultations fees from Astra Zeneca, Bristol, Janssen, and Lundbeck; has received research funding from Janssen, Eli Lilly, Lundbeck, Novartis, and Roche; and is a shareholder of Biomolecular Technology Ltda.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hoexter, M.Q., Fadel, G., Felício, A.C. et al. Higher striatal dopamine transporter density in PTSD: an in vivo SPECT study with [99mTc]TRODAT-1. Psychopharmacology 224, 337–345 (2012). https://doi.org/10.1007/s00213-012-2755-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-012-2755-4